2. Search Result
Search Result
Results for "

Dimethylarginine

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

1

Biochemical Assay Reagents

18

Peptides

8

Natural
Products

1

Recombinant Proteins

6

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113216
    Asymmetric dimethylarginine
    5 Publications Verification

    NG,NG-Dimethylarginine

    		 Endogenous Metabolite NO Synthase Cardiovascular Disease Cancer
    Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a number of pathological states.
    Asymmetric dimethylarginine
  • HY-134124
    Glutathione ethyl ester

    		Reactive Oxygen Species (ROS) Metabolic Disease
    Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .
    Glutathione ethyl ester
  • HY-101410
    SDMA
    3 Publications Verification

    Symmetric Dimethylarginine; NG,NG'-Dimethyl-L-arginine

    		 Endogenous Metabolite NO Synthase NF-κB Inflammation/Immunology
    SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
    SDMA
  • HY-P10272
    Rusfertide

    PTG-300

    		 Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
    Rusfertide
  • HY-A0248A
    Polymyxin B1
    1 Publications Verification

    		 Bacterial Infection
    Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1
  • HY-W016288
    Naphthalene-2,3-dicarboxaldehyde
    1 Publications Verification

    2,3-Naphthalenedicarboxaldehyde; Naphthalene-2,3-dialdehyde

    		 Fungal Infection
    Naphthalene-2,3-dicarboxaldehyde (NDA) is an effective inhibitor of Candida albicans aspartate semialdehyde dehydrogenase (ASADH), with a Ki value of 45 μM. Naphthalene-2,3-dicarboxaldehyde targets ASADH in the aspartate biosynthetic pathway of Candida albicans. Naphthalene-2,3-dicarboxaldehyde reacts with primary amines to generate highly fluorescent and stable derivatives. Naphthalene-2,3-dicarboxaldehyde serves as a fungistatic agent and a fluorogenic derivatization reagent. Naphthalene-2,3-Dicarboxaldehyde can be used for the research of candidiasis .
    Naphthalene-2,3-dicarboxaldehyde
  • HY-P1108A
    Astressin 2B TFA
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B TFA
  • HY-P1108
    Astressin 2B
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B
  • HY-101410S
    SDMA-d6

    Symmetric Dimethylarginine-d6; NG,NG'-Dimethyl-L-arginine-d6

    		 Endogenous Metabolite Inflammation/Immunology
    SDMA-d6 is the deuterium labeled SDMA. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity .
    SDMA-d6
  • HY-113216BS
    Asymmetric-dimethylarginine-d6 dihydrochloride

    NG,NG-Dimethylarginine-d6 dihydrochloride

    		 Endogenous Metabolite NO Synthase Others
    Asymmetric-dimethylarginine-d6 (dihydrochloride) is the deuterium labeled Asymmetric-dimethylarginine dihydrochloride .
    Asymmetric-dimethylarginine-d6 dihydrochloride
  • HY-113216B
    Asymmetric dimethylarginine dihydrochloride

    NG,NG-Dimethylarginine dihydrochloride

    		 NO Synthase Cardiovascular Disease Cancer
    Asymmetric dimethylarginine dihydrochloride is an endogenous NO synthase inhibitor that reduces NO production, which contributes to endothelial dysfunction and cardiovascular disease .
    Asymmetric dimethylarginine dihydrochloride
  • HY-16958
    PD 404182
    1 Publications Verification

    		 Antibiotic Dimethylargininase (DDAH) Inflammation/Immunology
    PD 404182 is a potent and competitive inhibitor of human dimethylarginine dimethylaminohydrolase 1 (DDAH1), with an IC50 of 9 μM. PD 404182 exhibits antiangiogenic and antiviral activity in vitro .
    PD 404182
  • HY-101410R
    SDMA (Standard)

    Symmetric Dimethylarginine (Standard); NG,NG'-Dimethyl-L-arginine (Standard)

    		 Reference Standards Endogenous Metabolite NO Synthase NF-κB Inflammation/Immunology
    SDMA (Standard) is the analytical standard of SDMA. This product is intended for research and analytical applications. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity. SDMA, a novel kidney biomarker, permits earlier diagnosis of kidney disease than traditional creatinine testing.
    SDMA (Standard)
  • HY-159728
    PROTAC PRMT3 degrader 1

    		PROTACs Histone Methyltransferase Apoptosis Early 2 Factor (E2F) c-Myc Cancer
    PROTAC PRMT3 degrader 1 is a selective PRMT3 PROTAC degrader with a DC50 of 2.566 μM. PROTAC PRMT3 degrader 1 forms a ternary complex with MDM2 E3 ubiquitin ligase to induce proteasomal and neddylation-dependent degradation of PRMT3. PROTAC PRMT3 degrader 1 activates intrinsic apoptosis, endoplasmic reticulum stress signaling pathways. PROTAC PRMT3 degrader 1 downregulates E2F, MYC, oxidative phosphorylation pathways. PROTAC PRMT3 degrader 1 reduces cellular asymmetric dimethylarginine (ADMA) levels. PROTAC PRMT3 degrader 1 inhibits acute leukemia cell growth. PROTAC PRMT3 degrader 1 acts with glycolysis inhibitor 2-DG to reduce ATP production, induce intrinsic apoptosis, drive synergistic antiproliferative effects. PROTAC PRMT3 degrader 1 can be used for the research of acute leukemia .
    PROTAC PRMT3 degrader 1
  • HY-P10143
    MMP-2/MMP-9 Substrate

    Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt

    		 MMP Others
    MMP-2/MMP-9 Substrate (Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt) is a synthetic chromogenic polypeptide substrate whose core structure mimics the cleavage sites of MMP-2 and MMP-9 (gelatinase A and B) in collagen. After being hydrolyzed by collagenase, MMP-2/MMP-9 Substrate reacts with 4,4'-dithiodipyridine or Ellman's Reagent via its thiol fragment to produce a product with ultraviolet absorption properties .
    MMP-2/MMP-9 Substrate
  • HY-A0248AS
    Polymyxin B1-d7 TFA

    		Isotope-Labeled Compounds Bacterial Infection
    Polymyxin B1-d7 TFA is the deuterium labeled Polymyxin B1 TFA (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1-d7 TFA
  • HY-P10563
    Noraramtide

    BHV-1100

    		 CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide
  • HY-113216R
    Asymmetric dimethylarginine (Standard)

    NG,NG-Dimethylarginine (Standard)

    		 Reference Standards Endogenous Metabolite NO Synthase Cardiovascular Disease Cancer
    Hesperetin (Standard) is the analytical standard of Hesperetin. This product is intended for research and analytical applications. Hesperetin is a natural flavanone, and acts as a potent and broad-spectrum inhibitor against human UGT activity. Hesperetin regulates apoptosis.
    Asymmetric dimethylarginine (Standard)
  • HY-158143
    AZD3470

    		Histone Methyltransferase Apoptosis Cancer
    AZD3470 is an orally active MTA-cooperative PRMT5 inhibitor, selective for MTAP-deficient tumors. AZD3470 induces cell cycle G2/M phase alterations, DNA damage, apoptosis, and symmetric dimethylarginine reduction. AZD3470 alters alternative splicing, increases skipped exon events in DNA repair and cell cycle pathways, and inhibits cancer cell proliferation and tumor growth. AZD3470 can be used for the research of non-small cell lung cancer and MTAP-deleted solid tumors .
    AZD3470
  • HY-P3066
    SKF 100398

    d(CH2)5Tyr(Et)VAVP

    		 Vasopressin Receptor Metabolic Disease
    SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
    SKF 100398
  • HY-168263
    PRMT5-IN-45

    		Histone Methyltransferase Apoptosis Cancer
    PRMT5-IN-45 (compound 36) is a potent and selective PRMT5 inhibitor with an IC50 of 3 nM. PRMT5-IN-45 potently reduces the level of symmetric dimethylarginines (sDMA) and inhibits the proliferation of MOLM-13 cell lines by inducing apoptosis and cell cycle arrest .
    PRMT5-IN-45
  • HY-113216AS
    Asymmetric dimethylarginine-d7 hydrochloride

    NG,NG-Dimethylarginine-d7 hydrochloride

    		 Endogenous Metabolite Others
    Asymmetric dimethylarginine-d7 (hydrochloride) is the deuterium labeled Asymmetric dimethylarginine hydrochloride .
    Asymmetric dimethylarginine-d7 hydrochloride
  • HY-113216S
    Asymmetric dimethylarginine-d7 hydrochloride hydrate

    NG,NG-Dimethylarginine-d7 hydrochloride hydrate

    		 Isotope-Labeled Compounds Endogenous Metabolite NO Synthase Cardiovascular Disease Cancer
    Asymmetric dimethylarginine-d7 (hydrochloride hydrate) is the deuterium labeled Asymmetric dimethylarginine. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a num
    Asymmetric dimethylarginine-d7 hydrochloride hydrate
  • HY-P4308
    Z-Pro-Pro-aldehyde-dimethyl acetal

    		Prolyl Endopeptidase (PREP) Neurological Disease
    Z-Pro-Pro-aldehyde-dimethyl acetal is a potent inhibitor of prolyl endopeptidase (PREP), a cytoplasmic serine endoprotease (IC50= 12 nM). Z-Pro-Pro-aldehyde-dimethyl acetal plays an important role in cognitive dysfunction in aging and neurodegenerative diseases including Alzheimer's disease .
    Z-Pro-Pro-aldehyde-dimethyl acetal
  • HY-P10828
    MAPI

    		Virus Protease Infection Inflammation/Immunology
    MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection .
    MAPI
  • HY-101410A
    SDMA (p-hydroxyazobenzene-p′-sulfonate)

    Symmetric Dimethylarginine (p-hydroxyazobenzene-p′-sulfonate); NG,NG'-Dimethyl-L-arginine (p-hydroxyazobenzene-p′-sulfonate)

    		 Endogenous Metabolite NO Synthase NF-κB Inflammation/Immunology
    SDMA p-hydroxyazobenzene-p′-sulfonate is the p-hydroxyazobenzene-p′-sulfonate salt form of SDMA (HY-101410). SDMA p-hydroxyazobenzene-p′-sulfonate is an endogenous inhibitor of nitric oxide synthase (NO synthase) activity. SDMA p-hydroxyazobenzene-p′-sulfonate is an activator for NF-κB, and promotes the expression of IL-6 and TNF-α. SDMA p-hydroxyazobenzene-p′-sulfonate is stable in serum and plasma, and can be used as a kidney biomarker of hepatic and renal dysfunction .
    SDMA (p-hydroxyazobenzene-p′-sulfonate)
  • HY-P6053
    KK-103

    		Opioid Receptor Neurological Disease
    KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .
    KK-103
  • HY-178028
    PRMT5-IN-53

    		Histone Methyltransferase Cancer
    PRMT5-IN-53 is a gut-restricted and orally active PRMT5 inhibitor with pIC50s of ≥ 9.7 against hPRMT5 and mPRMT5. PRMT5-IN-53 binds to the PRMT5:MEP50 complex with a KD of 11.3 pM. PRMT5-IN-53 effectively inhibits PRMT5 locally in the intestines of mice, significantly reducing the number and area of polyps, while avoiding systemic hematological toxicity (such as anemia, neutropenia). PRMT5-IN-53 can be used for the study of colorectal cancer especially for familial adenomatous polyposis (FAP) .
    PRMT5-IN-53
  • HY-175821
    PRMT1-IN-3

    		Histone Methyltransferase Apoptosis Cancer
    PRMT1-IN-3 is a potent protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 4.11 μM. PRMT1-IN-3 inhibits PRMT6 and PRMT8 with IC50s of 23.3 and 30.1 μM. PRMT1-IN-3 suppresses asymmetric dimethylarginine (ADMA) levels and histone H4R3me2a modification in triple-negative breast cancer (TNBC) cells. PRMT1-IN-3 induces cell cycle arrest, apoptosis, and inhibits migration and colony formation in MDA-MB-231 cells. PRMT1-IN-3 acts as chemotherapeutic sensitizers for Paclitaxel (HY-B0015). PRMT1-IN-3 can be used for the study of TNBC .
    PRMT1-IN-3
  • HY-141876
    PRT543

    		Histone Methyltransferase Notch PI3K Akt Bcl-2 Family DNA/RNA Synthesis Cancer
    PRT543 is an orally active selective PRMT5 inhibitor. PRT543 reduces intracellular symmetric dimethylarginine (sDMA) levels, downregulates the expression of genes related to DNA damage repair and DNA replication pathways, and induces abnormal alternative splicing. PRT543 inhibits the MYB, NOTCH1 and PI3K/AKT signaling pathways, promotes nuclear translocation of FOXO1, upregulates the pro-apoptotic protein BAX, and enhances cellular sensitivity to BCL-2 inhibition. PRT543 disrupts the normal RNA splicing process and exerts a synthetic lethal effect on myeloid tumor cells carrying splicing factor mutations. PRT543 can be used in research related to various cancers including breast cancer, ovarian cancer and acute myeloid leukemia .
    PRT543
  • HY-129450
    Ethyl-L-NIO hydrochloride

    		Others Others
    Ethyl-L-NIO hydrochloride is a potent and competitive human dimethylarginine dimethylaminohydrolase 1 (hDDAH-1) inhibitor with an IC50 of 70 μM and a Ki of 32 μM .
    Ethyl-L-NIO hydrochloride
  • HY-16958R
    PD 404182 (Standard)

    		Antibiotic Dimethylargininase (DDAH) Reference Standards Inflammation/Immunology
    Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .
    PD 404182 (Standard)
  • HY-133126A
    hDDAH-1-IN-1 TFA

    		NO Synthase Inflammation/Immunology Cancer
    hDDAH-1-IN-1 TFA (compound 8a) is a potent and selective non-amino acid catalytic site inhibitor of human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1), with a Ki of 18 μM .
    hDDAH-1-IN-1 TFA
  • HY-133145A
    hDDAH-1-IN-2 sulfate

    		NO Synthase Inflammation/Immunology Cancer
    hDDAH-1-IN-2 is a selective, orally active human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1) inhibitor. hDDAH-1-IN-2 reveals an excellent profile regarding cell toxicity/viability .
    hDDAH-1-IN-2 sulfate
  • HY-133145
    hDDAH-1-IN-2

    		Drug Intermediate Neurological Disease Inflammation/Immunology
    hDDAH-1-IN-2 is a selective, orally active human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1) inhibitor. hDDAH-1-IN-2 reveals an excellent profile regarding cell toxicity/viability .
    hDDAH-1-IN-2
  • HY-133126
    hDDAH-1-IN-1

    		NO Synthase Dimethylargininase (DDAH) Inflammation/Immunology Cancer
    hDDAH-1-IN-1 (compound 8a) is a potent and selective non-amino acid catalytic site inhibitor of human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1), with a Ki of 18 μM. DDAH mediates ADMA metabolism, thereby regulating nitric oxide production in a variety of disease states .
    hDDAH-1-IN-1
  • HY-CE01571
    N,N-Dimethylarginine-CoA

    N,N-Dimethylarginine-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    N,N-Dimethylarginine-CoA (N,N-Dimethylarginine-coenzyme A) is a coenzyme A derivative .
    N,N-Dimethylarginine-CoA
  • HY-139135
    Methyl-L-NIO hydrochloride

    		NO Synthase Others
    Methyl-L-NIO (compound 2d) hydrochloride is a potential selective inhibitor (IC50: 70 μM) of dimethylarginine dimethylaminohydrolase hDDAH. Methyl-L-NIO also has inhibitory activity against NO synthase. The inhibition rates of Methyl-L-NIO on different isoforms of NO synthase at a concentration of 100 μM are 77% (nNOS), 20% (eNOS), and 72% (iNOS) respectively; the inhibition rates at a concentration of 1 mM are 100% (nNOS), 85% (eNOS), 100% (iNOS) .
    Methyl-L-NIO hydrochloride
  • HY-178274
    SKLB06329

    		Histone Methyltransferase Apoptosis Cancer
    SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs). SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research .
    SKLB06329
  • HY-P2592
    Ro 23-7014

    		Cholecystokinin Receptor Others
    Ro 23-7014 is an appetite suppressant. Ro 23-7014 is an analog of cholecystokinin (CCK-7) .
    Ro 23-7014
  • HY-CE01606
    N3,N4-Dimethylarginine-CoA

    N3, N4-Dimethylarginine-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    N3,N4-Dimethylarginine-CoA (N3, N4-Dimethylarginine-coenzyme A) is a coenzyme A derivative .
    N3,N4-Dimethylarginine-CoA
  • HY-125628
    Kahalalide A

    		Endogenous Metabolite Infection
    Kahalalide A is an anti-mycobacterial compound with antimicrobial activity. Kahalalide A is derived from the marine mollusk Elysia rufescens. Kahalalide A has attracted extensive attention in natural product research due to its potential medicinal value .
    Kahalalide A
  • HY-182275
    PROTAC PRMT1 degrader-1

    		PROTACs Histone Methyltransferase Cancer
    PROTAC PRMT1 degrader-1 (compound 4) is a PRMT1 PROTAC degrader, with a DC50 of 0.77 μM (MCF-7 cells). PROTAC PRMT1 degrader-1 recruits the CRBN E3 ubiquitin ligase to induce proteasome-dependent degradation of PRMT1; it also forms a ternary complex with PRMT1 and CRBN, promoting ubiquitination and subsequent proteasomal degradation of PRMT1. PROTAC PRMT1 degrader-1 reduces the level of asymmetric dimethylarginine in cancer cells, as well as the level of asymmetric dimethylation of arginine 3 on histone H4, while inhibiting the growth of various cancer cells. PROTAC PRMT1 degrader-1 can be used in the research of breast cancer and melanoma .
    PROTAC PRMT1 degrader-1
  • HY-183568
    MAT2A-IN-26

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-26 is an orally active MAT2A inhibitor with a human IC50 of 17.53 nM. MAT2A-IN-26 inhibits the enzymatic activity of MAT2A, thereby reducing the levels of S-adenosylmethionine (SAM) and symmetric dimethylarginine (sDMA). MAT2A-IN-26 inhibits the proliferation of MTAP-deficient cancer cells and induces anti-tumor efficacy in xenograft models. MAT2A-IN-26 can be used in non-small cell lung cancer research .
    MAT2A-IN-26
  • HY-181260
    PRMT5-MTA-IN-8

    		Histone Methyltransferase Apoptosis Cancer
    PRMT5-MTA-IN-8 is an orally active PRMT5-MTA complex inhibitor (IC50 = 4.4 nM). PRMT5-MTA-IN-8 inhibits the intracellular production of symmetric dimethylarginine (SDMA) as well as the proliferation of MTAP-deficient cells. PRMT5-MTA-IN-8 exerts antitumor efficacy by inhibiting PRMT5, reducing SDMA levels and inducing tumor cell apoptosis in mouse models of triple-negative breast cancer. PRMT5-MTA-IN-8 can be used in research related to cancers such as triple-negative breast cancer .
    PRMT5-MTA-IN-8
  • HY-P11673
    Zabopegdutide

    		GLP Receptor Metabolic Disease
    Zabopegdutide is a glucagon and glucagon-like peptide 1 (GLP-1) receptor agonist. Zabopegdutide can be used for the study of obesity .
    Zabopegdutide
  • HY-A0248AS1
    Polymyxin B1-D-Leu-d7 TFA

    		Isotope-Labeled Compounds Bacterial Infection
    Polymyxin B1-D-Leu-d7 TFA is the deuterium labeled Polymyxin B1 (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1-D-Leu-d7 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: